Abstract 11302: Natural Heart Regeneration After Myocardial Infarction in Newborn Rats Provides Ultra-Long-Term Protection From Cardiac Dysfunction and Mortality
Hanjay WangHye Sook ShinDanielle MullisNicholas TranJinsuh JungMatthew WuStefan EldeYuanjia ZhuY. Joseph J WooStanford Univ,Stanford,CAStanford Med Sch,Stanford,CASTANFORD UNIV SCHOOL MEDICINE,Stanford,CA
DOI: https://doi.org/10.1161/circ.146.suppl_1.11302
IF: 37.8
2022-11-01
Circulation
Abstract:Circulation, Volume 146, Issue Suppl_1, Page A11302-A11302, November 8, 2022. Introduction:Newborn rats exhibit natural heart regeneration after myocardial infarction (MI), yielding no evidence of cardiac dysfunction or scar at 3 weeks post-MI. This phenotype is absent when MI occurs after 1 week of age. The long-term function of the regenerated heart and its impact on survival post-MI have not been studied. We hypothesized that natural heart regeneration preserves cardiac function and normalizes survival through adulthood.Methods:Wistar rat neonates (n=51) underwent left anterior descending coronary artery ligation on postnatal day 1 (P1, n=17) or postnatal day 9 (P9, n=12). Sham surgery was performed in littermates (P1 n=12, P9 n=10). The rats were observed for the entirety of their lifespan, reaching 18 months post-MI (equivalent to 45 human years) at the time of this analysis. Echocardiography was obtained at 15 months post-MI. After each mortality event, hearts were sectioned and stained with Masson's trichome.Results:Echocardiography at 15 months after P1 MI vs P1 sham surgery revealed no differences in left ventricular (LV) wall thickness (p=0.881, Fig 1A) or end-diastolic diameter (p=0.118, Fig 1B), and LV ejection fraction (EF) was sustained within normal limits (63.2% vs 68.5%, p=0.003, Fig 1C). In contrast, after P9 MI, severe LV wall thinning (p<0.001), massive LV dilation (p<0.001), and profoundly depressed EF were observed (41.8% vs 69.1%, p 0.999) and 3/12 (25.0%) in the P9 MI group (p=0.009).Conclusions:Natural heart regeneration mechanisms may offer long-term protection from LV dysfunction and mortality after cardiac injury, suggesting potential applications in congenital heart surgery and as a durable treatment for ischemic cardiomyopathy.
cardiac & cardiovascular systems,peripheral vascular disease